Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2023

Feb 10, 2023

30291_dirs_2023-02-10_9af13d32-b452-4856-a775-c7fc2cdb2c55.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2023-02-08

Reporting Person: MCDONNELL MICHAEL R (EVP, Chief Financial Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-02-08 Restricted Stock Unit $0 A 7005 Acquired 2026-02-08 Common Stock (7005) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 6745 Direct

Footnotes

F1: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023.